E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
PTSD and anxiety disorders |
|
E.1.1.1 | Medical condition in easily understood language |
PTSD and anxiety disorders |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of this project is to investigate CBD as a new medicine to target the ECS in the reduction of anxiety symptoms. |
|
E.2.2 | Secondary objectives of the trial |
Subsidiary aims of the project are to investigate the effects of CBD on fear extinction and extinction consolidation, stress regulation and sleep. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
In order to be eligible to participate in this study, a subject must meet all of the following criteria: • Dutch military personnel or veteran • Age between 18-65 • Waiting for therapy for the treatment of PTSD and/or anxiety disorders
|
|
E.4 | Principal exclusion criteria |
A potential subject who meets any of the following criteria will be excluded from participation in this study: • Severe co-morbidity (severe major depressive or bipolar disorder and/or psychosis) • Alcohol and/or drug dependence • Inability to adequately read or speak Dutch • (a history of) epilepsy or brain damage, cardiac, renal or liver abnormalities • (a history of) allergies to medication (adverse reactions or rash) • Individuals taking certain medications known to have potential interactions with CBD (i.e., steroids, HMG-CoA reductase inhibitors, calcium channel blockers, antihistamines, antivirals, immune modulators, benzodiazepines, anti-arrhythmic, antibiotics, anesthetics, antipsychotics, antidepressants, anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotensin II blockers, oral hypoglycemic agents, and sulfonylureas) • Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or THC-containing product within 30 days of eligibility screening. • Individuals that had been diagnosed with intestinal, liver, or renal diseases that would affect absorption or clearance of CBD • For women: pregnant, a wish to become pregnant, or nursing
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of the study is the effects of CBD on anxiety symptoms as measured with the Beck Anxiety Inventory (BAI). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
This will be measured pre waitlist, 1 week after CBD administration, post waitlist and at 3 month follow up. For the main analysis we compare the pre and post waitlist score on anxiety symptoms. |
|
E.5.2 | Secondary end point(s) |
The secondary endpoint of the study are: - The effect of CBD on fear extinction and consolidation - The effect of CBD on stress regulation - The effect of CBD on sleep
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The effect of CBD on fear extinction and consolidation - This will be measured pre and post waitlist - Parameters are subjective fear and expectancy, skin conductance response and startle response The effect of CBD on stress regulation - This will be measured post waitlist - Parameters are subjective stress, skin conductance, cortisol response and heart rate. The effect of CBD on sleep - This will be measured subjectively pre and post waitlist - This will be measured objectively with a actiwatch during the weeks of CBD administration
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trials is defined as the last participants completing the post waitlist measurements |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |